Proteinuria: Clinical Trials

14 trials for Proteinuria, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 terminated. 14 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 214Terminated 14
Phase 31Terminated 1

Follow Proteinuria: new trials by email Literature Review of Proteinuria trials Research Report on Proteinuria

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care - Lupus Nephritis
Phase 2TerminatedNovartis Pharmaceuticals812022-08-102026-11-12
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
AT-1501 - IgA Nephropathy, IgAN
Phase 2TerminatedEledon Pharmaceuticals242022-03-212024-03-26
TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension
Dapagliflozin 10Mg Tab, Placebo - Albuminuria
Phase 2TerminatedUniversity Medical Center Groningen92022-02-032024-04-17
Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria
Lisinopril, Placebo Oral Tablet - HIV/AIDS, Albuminuria
Phase 2TerminatedVanderbilt University Medical Center662021-04-012025-06-26
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
AZD5718, Dapagliflozin 10 mg, Placebo - Chronic Kidney Disease
Phase 2TerminatedAstraZeneca6132020-10-012024-12-20
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
AVB-S6-500 - IgA Nephropathy
Phase 2TerminatedAravive, Inc.12019-11-272022-02-10
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
Isosorbide Mononitrate, Placebo oral tablet - Kidney Injury, Proteinuria
Phase 2TerminatedThe University of Texas Health Science Center, Houston92019-09-262022-08-03
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
PF-06730512 - Focal Segmental Glomerulosclerosis (FSGS)
Phase 2TerminatedPfizer472018-10-152024-04-18
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
CCX140-B - Focal Segmental Glomerulosclerosis
Phase 2TerminatedAmgen52018-10-012025-03-17
Efficacy and Safety of Atacicept in IgA Nephropathy
Placebo, Atacicept 25 mg, Atacicept 75 mg - IgA Nephropathy
Phase 2TerminatedEMD Serono Research & Development Institute, Inc.162017-01-312021-02-25
Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
Alirocumab, Alirocumab placebo, Atorvastatin - Nephrotic Syndrome
Phase 2TerminatedGloria Vega32017-01-012022-08-19
Preventing Sickle Cell Kidney Disease
Losartan - Anemia, Sickle Cell, Sickle Cell Disease
Phase 2TerminatedUniversity of Alabama at Birmingham12015-04-012024-04-03
Rhubarb and Angiotensin Converting Enzyme Inhibitor
rhubarb extract, placebo - Diabetic Kidney Disease
Phase 2TerminatedWake Forest University82008-01-012018-12-13
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
infliximab, placebo - Lupus Erythematosus, Systemic, Lupus Nephritis
Phase 2 / Phase 3TerminatedMedical University of Vienna12006-09-012009-10-05

Narrower conditions

Albuminuria (3)  ·  Glomerulonephritis, IGA (3)  ·  Kidney Diseases (3)  ·  Diabetic Nephropathies (2)  ·  Glomerulosclerosis, Focal Segmental (2)  ·  Hypertension (2)  ·  Lupus Erythematosus, Systemic (2)  ·  Lupus Nephritis (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Anemia, Sickle Cell (1)  ·  Diabetes Mellitus (1)  ·  Dyslipidemias (1)  ·  Genetic Predisposition to Disease (1)  ·  Glomerulonephritis (1)

Broader conditions

Female Urogenital Diseases (14)  ·  Female Urogenital Diseases and Pregnancy Complications (14)  ·  Male Urogenital Diseases (14)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Signs and Symptoms (14)  ·  Urination Disorders (14)  ·  Urogenital Diseases (14)  ·  Urologic Diseases (14)  ·  Urological Manifestations (14)  ·  Kidney Diseases (9)  ·  Glomerulonephritis (6)  ·  Immune System Diseases (6)  ·  Nephritis (6)  ·  Autoimmune Diseases (5)

Interventions

dapagliflozin (2)  ·  AZD5718 (1)  ·  Atorvastatin (1)  ·  CCX140-B (1)  ·  Infliximab (1)  ·  Lisinopril (1)  ·  Losartan (1)  ·  PF-06730512 (1)  ·  Standard of Care (1)  ·  TACI receptor-IgG Fc fragment fusion protein (1)  ·  alirocumab (1)  ·  iptacopan (1)  ·  isosorbide-5-mononitrate (1)

Sponsors

Amgen (1)  ·  Aravive, Inc. (1)  ·  AstraZeneca (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  Eledon Pharmaceuticals (1)  ·  Gloria Vega (1)  ·  Medical University of Vienna (1)  ·  Novartis Pharmaceuticals (1)  ·  Pfizer (1)  ·  The University of Texas Health Science Center, Houston (1)  ·  University Medical Center Groningen (1)  ·  University of Alabama at Birmingham (1)  ·  Vanderbilt University Medical Center (1)  ·  Wake Forest University (1)

Countries

United States (10)  ·  Germany (4)  ·  United Kingdom (4)  ·  Japan (3)  ·  Malaysia (3)  ·  Poland (3)  ·  Argentina (2)  ·  Brazil (2)  ·  France (2)  ·  Mexico (2)  ·  Netherlands (2)  ·  Philippines (2)  ·  Spain (2)  ·  Ukraine (2)  ·  Australia (1)

Top investigators

C. William Wester, MD, MPH (1)  ·  Falk Hiepe, MD (1)  ·  Francoise Desir (1)  ·  Gloria L Vega, PhD (1)  ·  Hiddo J. L. Heerspink (1)  ·  Jaya Kala, MD (1)  ·  Jeffrey D Lebensburger, DO, MSPH (1)  ·  John Burkart, MD (1)  ·  Josef S Smolen, MD (1)  ·  Marc Bijl, MD (1)  ·  Martin Aringer, MD (1)  ·  Michael Concepcion, MD (1)  ·  Muktar H. Aliyu, MD, DrPH (1)

Results publications

PMID 34169203, PMID 34805632, PMID 37528520

NIH funding

2016 (1), 2019 (1), K23HL127100 (1), R21AT002367 (1), U01DK112271 (1)